Abstract. Increasing evidence implicates angiogenesis in the pathogenesis of fibrotic lung diseases. Distinct angiogenic profiles may, in part, explain differences in immunopathogenesis, clinical course and prognosis. The aim of the study was to seek evidence of involvement of the angiogenic axis Angiopoietin-1 and -2 and their tyrosine kinase receptor, Tie-2 in pathogenesis of idiopathic pulmonary fibrosis (IPF) and interstitial pneumonias associated to collagen tissue disorders (CTD-IPs). We prospectively studied 36 patients with IPF, 23 patients with CTD-IP and 10 healthy subjects. Ang-1, Ang-2 and Tie-2 mRNA expression and protein levels were measured in bronchoalveolar lavage fluid pellets and supernatants, respectively. A statistically significant decrease of Ang-1 protein level has been found in IPF in comparison to controls (p=0.02). We also detected an increased expression of Ang-2 protein in IPF in comparison to CTD-IPs. A significant co-expression was detected between Ang-2 and Tie-2 in protein level (p=0.007) in IPF group. In conclusion, a suppression of the angiogenetic factor Ang-1 was observed at the protein level in IPF which may be important in the pathogenesis of this devastating disease. A differential angiogenetic profile regarding Ang-2 was detected between IPF and CTD-IPs.
Introduction
Angiogenesis, the growth of blood vessels from existing ones, is a fundamental biological process that controls embryonic development but is also implicated in numerous life-threatening processes such as pathogenesis of fibroproliferative lung diseases including idiopathic interstitial pneumonias (IIPs) and interstitial pneumonias associated with collagen tissue disorders (CTD-IPs) (1) (2) (3) (4) . It has a significant contribution to the fibroproliferation and extracellular matrix deposition which characterize these diseases (5, 6) . Angiogenesis is controlled by the interplay of numerous positive and negative factors (7, 8) . It is still controversial whether angiogenesis has a negative or a positive regulatory role in the pathogenesis of fibrosis.
The concept of vascular remodelling was first raised by Turner-Warwick in IPF (1) . Two elegant morphological studies have confirmed the presence of vascular remodelling in IPF by demonstrating that this process is active in the areas immediately adjacent to fibroblastic foci whereas there is a decreased vascular density within the fibroblastic foci (2, 3) . Moreover, in the study by Renzoni et al this observation was also made in a CTD with pulmonary involvement such as fibrosing alveolitis associated with systemic sclerosis (2) . Keane et al demonstrated angiogenic activity in a large number of lung samples with idiopathic pulmonary fibrosis (9) , and Ebina et al (10) found both increased capillary density and vascular regression in the same lung at different sites, raising the question of whether angiogenesis is positively or negatively regulated during the process of pulmonary fibrosis.
The biological axis of Angiopoietin-1 and -2 (Ang-1 and -2) and their endothelium-specific receptor tyrosine kinase Tie-2, is implicated in the process of angiogenesis. Ang-1 stabilizes blood vessels by promoting the interaction between endothelial cells and the surrounding extracellular matrix whereas Ang-2 acts as a natural antagonist of Ang-1 by binding to Tie-2 competitively and destabilising blood vessels (11) . However, the vessels destabilized by the action of Ang-2 may not regress but undergo angiogenic changes in the presence of angiogenic factors such as vascular endothelial growth factor (VEGF).
The role of this axis has been explored in cancer growth, maintenance and metastasis (11) , in the development of chronic hypoxic pulmonary hypertension (12) , in chronic obstructive pulmonary disease (13) , in asthma (14) and in the pathogenesis of exudative pleural effusions (15) .
The purpose of the current study was to investigate the implication of the biological axis Ang-1 and -2/Tie-2 in the pathogenesis of idiopathic and autoimmune lung fibrosis evaluating the mRNA expression and the protein level of its components in the bronchoalveolar lavage fluid (BALF). CTD-IPs. The diagnosis was based on clinical and HRCT criteria in accordance with the international societies guidelines (17) (18) (19) . In detail, the following patients were studied: a) 10 patients with Rheumatoid Arthritis (RA) and HRCT characteristics of UIP, b) 9 patients with systemic sclerosis (SSc) and HRCT appearance of nonspecific interstitial pneumonia (NSIP), c) 2 patients with systemic lupus erythematous (SLE) one with HRCT features of NSIP and one with HRCT features of UIP, d) one patient with Sjogren syndrome and histologolically proven fibrotic NSIP, and finally e) one patient with dermatomyositis-polymyositis and HRCT features of NSIP.
Investigation of angiogenetic axis

Pulmonary function tests.
All patients were evaluated with complete pulmonary function tests (PFTs) including spirometry, measurement of lung volumes and diffusion capacity. Spirometry, lung volumes using the helium-dilution technique and T L,CO (corrected for haemoglobin) using the single-breath technique were performed using a computerised system (Jaeger 2.12; MasterLab, Würzburg, Germany). Predicted values were obtained from the standardised lung function testing of the European Coal and Steel Community, Luxembourg (1993).
BAL fluid processing. BALF was obtained from all patients and processed as previously described (4).
RNA isolation and reverse transcription-polymerase chain reaction
RNA extraction and reverse transcription. Total RNA was extracted from each specimen using a power homogenizer and the TRIzol ® reagent (Invitrogen, Carlsband, CA) according to the manufacturer's instructions. cDNA was synthesized using the Strascript reverse transcriptase kit (Stratagene, La Jolla, CA) as previously described (4).
Real-time RT-PCR.
Ang-1, Ang-2 and Tie-2 mRNA expression was measured using a real-time RT-PCR assay with SYBR-Green I. Primers were designed to span introns. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control, in order to normalize Ang-1, Ang-2, Tie-2. Specifically, 1 μl cDNA from all patient and control samples was amplified in a PCR reaction containing 2X Brilliant SYBR-Green I QPCR Master mix, 300 nM of each primer and 30 μM ROX passive reference dye, in a final volume of 20 μl. After an initial denaturation at 95˚C for 10 min, the samples were subjected to 40 cycles of amplification, comprised of denaturation at 95˚C for 30 sec, annealing at appropriate temperature for each primer pair for 30 sec and elongation at 72˚C for 30 sec, followed by a melt curve analysis, in which the temperature was increased from 55˚C to 95˚C at a linear rate of 0.2˚C/sec.
Data collection was performed both during annealing and extension, with two measurements at each step, and at all times during melt curve analysis. In each PCR reaction two non-template controls were included. All PCR experiments were conducted on the Mx3000P real-time PCR thermal cycler using the software version 2.00 (Stratagene). To verify the results of the melt curve analysis, PCR products were analyzed by electrophoresis in 2% agarose gels, stained with ethidium bromide and photographed on a UV light transilluminator.
Primer sequences, annealing temperatures and PCR product length for all the genes analyzed, as well as for GAPDH, are shown in Table I . All reactions were run in triplicates, and peptide transcript levels were calculated and normalized to each specimen's housekeeping gene mRNA (GAPDH) as well as the appropriate calibrators, using the ΔΔCt method for relative quantification. Specifically, after Table I . Primer sequences used for quantitative real-time RT-PCR. 
amplification, standard curves were constructed from samples used in a series of consecutive dilutions, for both the gene of interest and the internal control (GAPDH). Ang-1, Ang-2, Tie-2 and GAPDH amplification efficiencies were the same, reaching 100%. IPF and control data were first normalized against variation in sample quality and quantity. Normalized values to GAPDH, ΔCts, were initially calculated using the following equation: ΔCt sample = Ct gene -Ct GAPDH .
Assay of angiogenic parameter protein levels using specific enzyme-linked immunosorbent assay. Human BALF protein levels of Ang-1, Ang-2 and Tie-2 were quantitated according to the manufacturer's protocol using ELISA kits (R&D Systems) and measurements were performed in the BALF supernatant. Human Ang-1, Ang-2 and Tie-2 had the lowest detectable limit of 5 and 10 pg·ml -1 , respectively.
Statistical analysis. Angiogenetic parameters and demographic characteristics were first evaluated by the one-sample Kolmogorov-Smirnov goodness of fit test, in order to determine whether they followed a normal distribution pattern. Depending on the results, Mann-Whitney test or T-test were used to examine their expression status between the groups. The non-parametric Spearman rank correlation was used to examine their relation pair-wise. Finally, the Chi-square (¯2) test was applied to evaluate the significant statistical differences in Ang-1, Ang-2, Tie-2 mRNA and protein expression status as well as gender (male/female) and smoking status (smokers, non-smokers, ex-smokers). p<0.05 were considered statistically significant. All statistical analyses were performed with SPSS 11.5 (SPSS, Chicago, IL, USA).
Results
The demographic and spirometric data of healthy controls, IPF and CTD-IP patients are shown in Table II . IPF patients were older than CTD-IPs and healthy subjects with the majority of them being males. There were more IPF patients who were current smokers as well as ex-smokers whereas most of the CTD-IPs patients have never smoked. Both patient groups had a significant decrease in the cardinal parameters of restrictive defect (TLC and DLco). - Table III . Expression profile of mRNA and protein levels of the genes. -
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was not expressed in our study groups. Tie-2 protein expression was detectable in 17/27 (62.4%), 9/15 (60%), and 8/10 (80%) in IPF, CTD-IPs and control subjects, respectively (Table III) .
mRNA expression of Ang-1 and -2/Tie-2 in patient groups and controls. We found no significant difference in mRNA expression of Ang-2 in our study groups (Table IV) .
Protein expression of Ang-1 and -2/Tie-2 in patient groups and controls. We found a statistically significant decrease of Ang-1 protein level in IPF in comparison to control subjects (mean ± SD, 0.24±0.14 versus 0.79±0.25, p=0.021). The increase of Ang-1 protein level in CTD-IP in comparison to IPF and control did not reach statistical significance. We detected no significant difference in Ang-2 and Tie-2 protein level in our study groups (Table IV and Fig. 1 ).
Correlations between angiogenic parameters. A significant pair-wise correlations between Ang-2 and Tie-2 in protein level was observed in IPF group (p=0.007 Spearman correlation).
Discussion
To the best of our knowledge this is the first study that investigated the role of Ang-1, Ang-2 and their receptor Tie-2 ---------------------------------------------------------------------------------------------------- - in the pathogenesis of IPF and CTD-IPs. We used the BAL fluid, a minimally invasive tool, in order to evaluate the mRNA and protein expression of these angiogenic parameters.
We observed a decrease of Ang-1 at the protein level in IPF patients compared to controls, suggesting a downregulation of angiogenesis. Additionally, a significant co-expression between Ang-2 and Tie-2 in protein level was found in the IPF group suggesting a possible increase of angiostatic activity in IPF. This could be a novel pathway involved in the pathogenetic process of IPF.
We also observed that Ang-2 protein was significantly expressed in more patients with IPF in comparison to CTD-IP and that Ang-2 protein levels were increased, although not significantly in IPF compared to CTD-IPs. This finding might be evidence of distinct angiogenic profile between IPF and CTD-IPs, which explains the well known difference in terms of prognosis and response to therapy between these two diseases (20) . Recently, our study group demonstrated that angiogenesis could differ between CTD-IPs and IPF showing a significantly higher level in both mRNA and protein expression of stromal cell derived factor-1· transcript 1 (SDF-1·-TR1), a potent angiogenic factor, in BAL fluid of patients with CTD-IPs in comparison to IPF patients (21) . In addition, we found a post-transcriptional overexpression of VEGF, a major angiogenic factor, in CTD-IPs when compared to patients with NSIP (21) . Moreover, we suggested that distinct angiogenic profiles could also explain differences in the pathogenesis and prognosis between fibrotic and granulomatous disorders (4, 22) .
It should be stressed that our study has some limitations that need consideration. It is not a morphological study since we have used BAL fluid and not lung tissue. This is due to the fact that surgical lung biopsy is often not warranted for the diagnosis of IPF (16) . On the other hand, surgical biopsy does not add more information on the diagnosis and prognosis of CTD-IP, except in cases with unusual high resolution computerised tomography scan appearances (20) . Moreover, CTD-IPs have better prognosis than IPF even when they present with a UIP pattern in lung biopsy (17) . Another limitation is the small number of CTD-IPs patients for whom it was not possible to analyze data separately for individual CTDs and for individual histologic pattern.
In conclusion, the current study is the first to investigate the angiogenetic axis of Angiopoietins-1 and -2 and their specific receptor Tie-2 in pulmonary fibrosis, both idiopathic and autoimmune. Our findings add to the understanding of the role of angiogenesis in the pathogenesis of lung fibrosis. However, further studies are needed to confirm these findings.
